FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:TOP1-C17orf64

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: TOP1-C17orf64
FusionPDB ID: 93064
FusionGDB2.0 ID: 93064
HgeneTgene
Gene symbol

TOP1

C17orf64

Gene ID

7150

124773

Gene nameDNA topoisomerase Ichromosome 17 open reading frame 64
SynonymsTOPI-
Cytomap

20q12

17q23.2

Type of geneprotein-codingprotein-coding
DescriptionDNA topoisomerase 1Scl-70 antigentopoisomerase (DNA) Itype I DNA topoisomeraseuncharacterized protein C17orf64
Modification date2020031320200313
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000361337, ENST00000269127, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score15 X 6 X 10=9007 X 5 X 4=140
# samples 2010
** MAII scorelog2(20/900*10)=-2.16992500144231
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(10/140*10)=-0.485426827170242
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: TOP1 [Title/Abstract] AND C17orf64 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: TOP1 [Title/Abstract] AND C17orf64 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)TOP1(39729993)-C17orf64(58503144), # samples:3
Anticipated loss of major functional domain due to fusion event.TOP1-C17orf64 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
TOP1-C17orf64 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
TOP1-C17orf64 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
TOP1-C17orf64 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneTOP1

GO:0006265

DNA topological change

14594810



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr20:39729993/chr17:58503144)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across TOP1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across C17orf64 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000361337TOP1chr2039729993+ENST00000269127C17orf64chr1758503144+23731558312217728
ENST00000361337TOP1chr2039729993+ENST00000269127C17orf64chr1758503143+23731558312217728

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000361337ENST00000269127TOP1chr2039729993+C17orf64chr1758503144+0.0040710760.99592894
ENST00000361337ENST00000269127TOP1chr2039729993+C17orf64chr1758503143+0.0040710760.99592894

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for TOP1-C17orf64

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
TOP1chr2039729993C17orf64chr17585031431558509IKYIMLNPSSRIKVTNVSCLETSSSA
TOP1chr2039729993C17orf64chr17585031441558509IKYIMLNPSSRIKVTNVSCLETSSSA

Top

Potential FusionNeoAntigen Information of TOP1-C17orf64 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
TOP1-C17orf64_39729993_58503143.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
TOP1-C17orf64chr2039729993chr17585031431558HLA-A30:08SSRIKVTNV0.99630.6762817
TOP1-C17orf64chr2039729993chr17585031431558HLA-A30:08RIKVTNVSC0.93940.75791019
TOP1-C17orf64chr2039729993chr17585031431558HLA-B73:01SRIKVTNVS0.96590.5813918
TOP1-C17orf64chr2039729993chr17585031431558HLA-C06:17SRIKVTNV0.96770.9783917
TOP1-C17orf64chr2039729993chr17585031431558HLA-C06:02SRIKVTNV0.96770.9783917
TOP1-C17orf64chr2039729993chr17585031431558HLA-C15:02SSRIKVTNV0.99860.7852817
TOP1-C17orf64chr2039729993chr17585031431558HLA-A30:01SSRIKVTNV0.99610.7729817
TOP1-C17orf64chr2039729993chr17585031431558HLA-B27:06SRIKVTNVSCL0.99990.7177920
TOP1-C17orf64chr2039729993chr17585031431558HLA-B27:08SRIKVTNVSCL0.99990.6509920
TOP1-C17orf64chr2039729993chr17585031431558HLA-B27:09SRIKVTNVSCL0.99980.7471920

Top

Potential FusionNeoAntigen Information of TOP1-C17orf64 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
TOP1-C17orf64_39729993_58503143.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
TOP1-C17orf64chr2039729993chr17585031431558DRB1-0303IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-0338IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-0338KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1117KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1117YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1117IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1152KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1152YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1152IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1189YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1189KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1401KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1401YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1401IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1402IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1405KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1405YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1405IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1407KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1407YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1407IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1408KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1408YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1408IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1418KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1418YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1418IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1419IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1423KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1423YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1423IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1424IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1426KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1426YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1426IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1428IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1428KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1435KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1435YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1435IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1438KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1438IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1438YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1439IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1441IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1442KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1443KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1443YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1443IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1445KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1445YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1445IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1446IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1447IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1448IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1448KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1449IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1450IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1450KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1451IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1454KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1454YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1454IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1456KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1456YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1456IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1458KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1458YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1458IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1459KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1459YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1459IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1460KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1460YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1460IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1462KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1462YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1462IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1464KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1464YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1470KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1470IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1470YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1471KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1472KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1472YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1475KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1475YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1475IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1482KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1482IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1482YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1486KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1486YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1486IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1487KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1487YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1487IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1488KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1488YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1488IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1489IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1490KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1490YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1490IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1491KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1491YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1491IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1493IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1493KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1494IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1495KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1495IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1495YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1496KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1496YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1496IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1497KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1497YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1497IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1498IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1499KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1499YIMLNPSSRIKVTNV217
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1499IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB1-1525IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0109IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0201IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0201KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0202IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0202KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0204IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0204KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0205IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0205KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0209IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0209KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0210IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0210KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0211IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0211KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0212IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0212KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0213IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0214IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0214KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0215IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0216IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0216KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0217IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0218IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0218KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0219IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0219KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0220IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0220KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0221IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0221KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0222IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0222KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0223IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0223KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0224IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0224KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0225IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0225KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0301IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0301KYIMLNPSSRIKVTN116
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0303IKYIMLNPSSRIKVT015
TOP1-C17orf64chr2039729993chr17585031431558DRB3-0303KYIMLNPSSRIKVTN116

Top

Fusion breakpoint peptide structures of TOP1-C17orf64

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6327NPSSRIKVTNVSCLTOP1C17orf64chr2039729993chr17585031431558

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of TOP1-C17orf64

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN6327NPSSRIKVTNVSCL-7.9962-8.1096
HLA-B14:023BVN6327NPSSRIKVTNVSCL-5.70842-6.74372
HLA-B52:013W396327NPSSRIKVTNVSCL-6.83737-6.95077
HLA-B52:013W396327NPSSRIKVTNVSCL-4.4836-5.5189
HLA-A11:014UQ26327NPSSRIKVTNVSCL-10.0067-10.1201
HLA-A11:014UQ26327NPSSRIKVTNVSCL-9.03915-10.0745
HLA-A24:025HGA6327NPSSRIKVTNVSCL-6.56204-6.67544
HLA-A24:025HGA6327NPSSRIKVTNVSCL-5.42271-6.45801
HLA-B44:053DX86327NPSSRIKVTNVSCL-7.85648-8.89178
HLA-B44:053DX86327NPSSRIKVTNVSCL-5.3978-5.5112
HLA-A02:016TDR6327NPSSRIKVTNVSCL-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of TOP1-C17orf64

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
TOP1-C17orf64chr2039729993chr17585031431019RIKVTNVSCCGAATCAAGGTGACAAATGTGTCATGC
TOP1-C17orf64chr2039729993chr1758503143817SSRIKVTNVAGTTCACGAATCAAGGTGACAAATGTG
TOP1-C17orf64chr2039729993chr1758503143917SRIKVTNVTCACGAATCAAGGTGACAAATGTG
TOP1-C17orf64chr2039729993chr1758503143918SRIKVTNVSTCACGAATCAAGGTGACAAATGTGTCA
TOP1-C17orf64chr2039729993chr1758503143920SRIKVTNVSCLTCACGAATCAAGGTGACAAATGTGTCATGCCTG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
TOP1-C17orf64chr2039729993chr1758503143015IKYIMLNPSSRIKVTATTAAATACATCATGCTTAACCCTAGTTCACGAATCAAGGTGACA
TOP1-C17orf64chr2039729993chr1758503143116KYIMLNPSSRIKVTNAAATACATCATGCTTAACCCTAGTTCACGAATCAAGGTGACAAAT
TOP1-C17orf64chr2039729993chr1758503143217YIMLNPSSRIKVTNVTACATCATGCTTAACCCTAGTTCACGAATCAAGGTGACAAATGTG

Top

Information of the samples that have these potential fusion neoantigens of TOP1-C17orf64

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCATOP1-C17orf64chr2039729993ENST00000361337chr1758503143ENST00000269127TCGA-C8-A273

Top

Potential target of CAR-T therapy development for TOP1-C17orf64

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to TOP1-C17orf64

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to TOP1-C17orf64

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource